Home › ArcherDx, HeliTec Partner on Cancer Dx Development

ArcherDx, HeliTec Partner on Cancer Dx Development

Apr 04, 2017

NEW YORK (GenomeWeb) – ArcherDx has partnered with HeliTec on the development of next-generation sequencing-based cancer diagnostics for the Chinese market, the companies announced today.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Sep
20
Featured Webinar

Latest Advances in Tumor Genomic Profiling for Challenging Samples

This webinar will discuss how next-generation sequencing (NGS) can help clinical research labs and pathologists save time, money, and samples compared to single-analyte oncology research assays.

Sep
21
Featured Webinar

Processing Challenging Tumor Samples via Automated Tissue Dissection and Extraction-Free Library Prep

This webinar will demonstrate a new approach that combines precise FFPE tumor isolation with extraction-free DNA/RNA library preparation to minimize material losses and reduce the amount of tissue input required for NGS analysis.

Sep
27
Featured Webinar

Large-scale, Prospective Tumor and Normal Sequence to Accelerate Biomarker Discovery and Guide Clinical Care

This webinar will present an in-depth look at how Memorial Sloan Kettering Cancer Center has developed and implemented a next-generation sequencing panel for mutational tumor profiling of advanced cancer patients.

What's Popular?

In Cancer

  1. Biocept, UT Southwestern Partner for ALK Liquid Biopsy Study

  2. Dutch Researchers Develop ThromboSeq Test to Detect Lung Cancer

  3. Cynvenio, St. Luke's Partner on Breast Cancer Study

  4. Applied Proteomics Looking to Outsource Sales Operations, Expand Assay Development

    Premium

  5. Diagenode to Commercialize Clinical Breast Cancer Test Based on New Epigenetic Signature

    Premium

Sponsorships

Privacy Policy.  Copyright © 2017 GenomeWeb LLC.  All Rights Reserved.